Last reviewed · How we verify

NCT03038464: SyPJI

Synovial Aspiration and Serological Testing in Two-stage Revision Arthroplasty of Prosthetic Joint Infection

Status unknown Last updated 25 April 2017
What this trial tests

trial testing Synovial biopsy in Diagnosis Prosthetic Joint Infection in 40 participants. Status unknown.

Timeline
1 November 2016
Primary endpoint
1 April 2019
1 May 2019

Quick facts

Lead sponsorTechnical University of Munich
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date1 November 2016
Primary completion1 April 2019
Estimated completion1 May 2019
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Technical University of Munich

Who can join

Adults 18 to 80, any sex, with Diagnosis Prosthetic Joint Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The two-stage protocol is gold standard in terms of infection control treating prosthetic joint infections of total hip and total knee arthroplasty. The antibiotic pause for diagnostic reasons before reconstruction (stage two) is discussed concerning persistence of infection and development of resistant bacterial strains. Serological markers and synovial analysis are common use to exclude persistence of infection. The investigators therefore asked 1) is the serological testing of c-reactive protein and leukocytes a valuable tool to predict a persistence of infection and 2) what is the role of synovial aspiration of PMMA Spacers on hip and knee joints.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Synovial biopsy

Trials testing the same drug.

Other Technical University of Munich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03038464.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing